Product Name
BRCA1, siRNA
Full Product Name
BRCA1 siRNA (Mouse)
Product Synonym Names
Breast cancer type 1 susceptibility protein homolog
Product Gene Name
BRCA1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P48754
Specificity
BRCA1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse BRCA1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of BRCA1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
BRCA1 sirna
siRNA to inhibit BRCA1 expression using RNA interference
Applications Tested/Suitable for BRCA1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for BRCA1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_033894.3
[Other Products]
NCBI GenBank Nucleotide #
NM_009764.3
[Other Products]
UniProt Primary Accession #
P48754
[Other Products]
UniProt Secondary Accession #
Q60957; Q60983; A2A4Q4[Other Products]
UniProt Related Accession #
P48754[Other Products]
Molecular Weight
198,795 Da
NCBI Official Full Name
breast cancer type 1 susceptibility protein homolog
NCBI Official Synonym Full Names
breast cancer 1
NCBI Official Symbol
Brca1 [Similar Products]
NCBI Protein Information
breast cancer type 1 susceptibility protein homolog
UniProt Protein Name
Breast cancer type 1 susceptibility protein homolog
Protein Family
BRCA1-A complex
UniProt Gene Name
Brca1 [Similar Products]
UniProt Entry Name
BRCA1_MOUSE
UniProt Comments for BRCA1
BRCA1: the BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Plays a central role in DNA repair by facilitating cellular response to DNA repair. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACC1 and preventing its dephosphorylation. Defects in BRCA1 are a cause of genetic susceptibility to breast cancer. Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association may be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts (via BRCT domains) with CTIP. Associates with RNA polymerase II holoenzyme. Interacts with SMC1 and COBRA1. Interacts (via BRCT domains) with BRIP1. Interacts with FANCD2 (ubiquitinated). Interacts with BAP1. Interacts with Artemis and claspin. Interacts with H2AFX (phosphorylated on S140). Interacts with CHK1. Interacts with BRCC3. Five human isoforms are produced by alternative splicing and alternative initiation. Isoform 1 and isoform 3 are widely expressed. Isoform 1 is largely nuclear, while isoforms 3 and 5 are cytoplasmic.
Protein type: Ubiquitin ligase; Ubiquitin conjugating system; Transcription, coactivator/corepressor; Tumor suppressor; EC 6.3.2.-; Nuclear receptor co-regulator
Cellular Component: ruffle; centrosome; protein complex; condensed nuclear chromosome; mitochondrial matrix; BRCA1-BARD1 complex; cytoplasm; plasma membrane; condensed chromosome; chromosome; nucleus; ribonucleoprotein complex
Molecular Function: enzyme binding; DNA binding; zinc ion binding; coenzyme F420-2 alpha-glutamyl ligase activity; RNA binding; metal ion binding; UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate-D-alanyl-D-alanine ligase activity; ubiquitin protein ligase binding; ubiquitin-protein ligase activity; ribosomal S6-glutamic acid ligase activity; damaged DNA binding; coenzyme F420-0 gamma-glutamyl ligase activity; ligase activity
Biological Process: genetic imprinting; dosage compensation, by inactivation of X chromosome; centrosome cycle; protein ubiquitination; negative regulation of histone H3-K4 methylation; positive regulation of histone H3-K4 methylation; fatty acid metabolic process; chromosome segregation; negative regulation of histone acetylation; DNA recombination; double-strand break repair; DNA replication; fatty acid biosynthetic process; negative regulation of fatty acid biosynthetic process; positive regulation of histone H3-K9 methylation; negative regulation of histone H3-K9 methylation; protein autoubiquitination; positive regulation of DNA repair; chordate embryonic development; postreplication repair; cell cycle; DNA repair; double-strand break repair via homologous recombination; regulation of cell proliferation; positive regulation of angiogenesis; DNA damage response, signal transduction resulting in induction of apoptosis; positive regulation of protein ubiquitination; response to estrogen stimulus; positive regulation of histone acetylation; positive regulation of transcription from RNA polymerase II promoter; response to ionizing radiation; lipid metabolic process; G2/M transition DNA damage checkpoint; negative regulation of transcription, DNA-dependent; centrosome duplication; response to DNA damage stimulus
Research Articles on BRCA1
1. work therefore ascribes novel roles for BRCA1 and CtIP in end-processing and fusion reactions at uncapped telomeres
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
